NZ748316A - Methods for treating conditions associated with masp-2 dependent complement activation - Google Patents
Methods for treating conditions associated with masp-2 dependent complement activationInfo
- Publication number
- NZ748316A NZ748316A NZ748316A NZ74831614A NZ748316A NZ 748316 A NZ748316 A NZ 748316A NZ 748316 A NZ748316 A NZ 748316A NZ 74831614 A NZ74831614 A NZ 74831614A NZ 748316 A NZ748316 A NZ 748316A
- Authority
- NZ
- New Zealand
- Prior art keywords
- masp
- antibody
- subject
- complement activation
- dependent complement
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Discloses a method of inhibiting MASP-2-dependent complement activation in a subject suffering from or at risk for developing Upshaw-Schulman Syndrome (USS) or thrombotic microangiopathy, or reducing the likelihood that a subject with USS will suffer clinical symptoms associated with congenital TPP comprising administering to the subject a composition comprising an 5 amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation.
Claims (9)
1. Use of an amount of a MASP-2 inhibitory monoclonal antibody or fragment thereof that specifically binds to a portion of SEQ ID NO:6 effective to inhibit MASP 5 dependent complement activation in the manufacture of a medicament for inhibiting MASP- 2-dependent complement activation in a subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA) secondary to cancer.
2. The use of Claim 1, wherein the MASP-2 inhibitory agent is to be 10 administered systemically to the subject in an amount effective to reduce the risk of developing TMA, or reduce the severity of TMA secondary to cancer.
3. The use of Claim 1, wherein the subject has previously undergone, or is currently undergoing, treatment with a terminal complement inhibitor that inhibits cleavage 15 of complement protein C5.
4. The use of Claim 1, wherein the medicament is to be administered to the subject with a terminal complement inhibitor that inhibits cleavage of complement protein
5. The use of Claim 4, wherein the terminal complement inhibitor is a humanized anti-C5 antibody or antigen-binding fragment thereof.
6. The use of Claim 4, wherein the terminal complement inhibitor is eculizumab.
7. The use of Claim 4, wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody and a human antibody.
8. The use of Claim 1, wherein the medicament is to be administered subcutaneously, intra-muscularly, intra-arterially, intravenously, or as an inhalant.
9. The use of claim 1, substantially as herein described with reference to any one 5 of the Examples and/or
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892283P | 2013-10-17 | 2013-10-17 | |
| NZ716896A NZ716896A (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ748316A true NZ748316A (en) | 2022-12-23 |
Family
ID=55587925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ748316A NZ748316A (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
| NZ716896A NZ716896A (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ716896A NZ716896A (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
Country Status (1)
| Country | Link |
|---|---|
| NZ (2) | NZ748316A (en) |
-
2014
- 2014-09-01 NZ NZ748316A patent/NZ748316A/en unknown
- 2014-09-01 NZ NZ716896A patent/NZ716896A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ716896A (en) | 2022-04-29 |
| NZ629683A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016118769A (en) | METHODS FOR TREATMENT OF CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT KIT ACTIVATION | |
| RU2018114903A (en) | COMPOSITIONS AND METHODS FOR INHIBITING MASP-1, AND / OR MASP-2, AND / OR MASP-3 FOR THE TREATMENT OF PAROXISMAL NIGHT HEMOGLOBINURIA | |
| NZ709997A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| MX2014001371A (en) | Pharmaceutical composition for treatment and/or prophylaxis of cancer. | |
| MX348579B (en) | Drug composition for cancer treatment and/or prevention. | |
| ES2617920T3 (en) | Methods for the treatment of disseminated intravascular coagulation by inhibiting the activation of MASP-2-dependent complement | |
| IN2014KN01715A (en) | ||
| BR112012019098A2 (en) | Medical treatment and/or a medicine constituent for prevention of cancer | |
| MX2014001374A (en) | Cancer treatment and/or prevention drug composition. | |
| JP2015521623A5 (en) | ||
| MX2014001375A (en) | Pharmaceutical composition for treatment and/or prophylaxis of cancer. | |
| Qin et al. | Complement Inhibitors in Age‐Related Macular Degeneration: A Potential Therapeutic Option | |
| BR112016001753A2 (en) | ANTIBODY, ANTIBODY OR FRAGMENT THEREOF, ANTIBODY COMPOSITION, CELL, PHARMACEUTICAL COMPOSITION, COMBINATION DRUG PRODUCT AND METHOD OF TREATMENT AND/OR PREVENTION OF CANCER | |
| EP2532365A4 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| JOP20200328A1 (en) | Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders | |
| RU2014122189A (en) | WAYS TO REDUCE THE FREQUENCY AND SEVERITY OF ACUTE ASTHMA | |
| Zhou et al. | A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b | |
| WO2015067755A3 (en) | Novel methods and antibodies for treating coagulapathy | |
| CR20200517A (en) | RGMa BINDING PROTEIN AND USE THEREOF | |
| CA3138401A1 (en) | Methods of treating neuropathy | |
| WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
| NZ748316A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| RU2017120031A (en) | METHOD FOR TREATING OR PREVENTING A STROKE | |
| JP2019530664A5 (en) | ||
| Kowalewska | Cryoglobulinemic glomerulonephritis—lessons from animal models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 01 SEP 2024 BY AJ PARK Effective date: 20230501 |